Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002679 · ClinicalTrials.gov registry record · Phase 2

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
89
Enrollment target
1
Study location

NCT00002679: Completed Phase 2 study of Breast Cancer, sponsored by Yale University.

NCT00002679 is a Phase 2 study of Breast Cancer that has completed, run by Yale University. The registered enrollment target is 89 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002679, a Phase 2 study of Breast Cancer, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
89 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating patients with stage II or stage III breast cancer who have four or more positive axillary lymph nodes.

Conditions Studied

Breast Cancer

Interventions

  • DRUG cyclophosphamide
  • DRUG paclitaxel
  • BIOLOGICAL filgrastim
  • DRUG doxorubicin hydrochloride
  • DRUG tamoxifen citrate

Study Locations (1)

Connecticut

  • Yale Comprehensive Cancer Center - New Haven

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 1994-02
Est. Completion 2002-01
Phase Phase 2
Yale University

1,492 total trials

What the finished NCT00002679 record still lists

NCT00002679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00002679 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00002679 about?

NCT00002679 is a clinical study titled "Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating pat...

What is the current status of trial NCT00002679?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 1994-02. Estimated completion is 2002-01.

What conditions does trial NCT00002679 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00002679?

The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG).

Who is sponsoring clinical trial NCT00002679?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002679 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002679's enrollment target sits among peer trials

89 622nd of 1224 higher than 601 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00002679, the US trial registry maintained by the National Library of Medicine. NCT00002679 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.